Trials / Unknown
UnknownNCT04664725
Drug-drug Interaction of SHR3680 With Repaglinide and Bupropion
A Single-center, Open-label, Fixed-sequence Phase I Drug-drug Interaction Clinical Study to Investigate the Pharmacokinetics of SHR3680 With Repaglinide (CYP2C8 Substrates) and Bupropion (CYP2B6 Substrates) in Prostate Cancer Patients
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- Male
- Age
- 45 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The DDI study had been designed to investigate the effect of SHR3680 on the pharmacokinetics of Repaglinide and Bupropion
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Repaglinide, Bupropion and SHR3680 | Single dose of oral administration of Repaglinide and Bupropion, Multiple dose of oral of SHR3680 |
Timeline
- Start date
- 2020-06-01
- Primary completion
- 2021-01-01
- Completion
- 2021-05-01
- First posted
- 2020-12-11
- Last updated
- 2020-12-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04664725. Inclusion in this directory is not an endorsement.